BioMerieux To Phase Out Some Microplate Production
Published: Dec 20, 2006
PARIS, Dec 20 (Reuters) - BioMerieux (BIOX.PA: Quote, Profile , Research), a French company that makes healthcare tests, said it would phase out production of microplate immunoassay at a facility in North Carolina next year, leading to a charge of around 7 million euros ($9.2 million) in its 2006 accounts. BioMerieux added in a statement released late on Tuesday that the charges would be mainly due to restructuring provisions, although the decision was not expected to have a material impact on the 2007 accounts. The business being phased out comprised tests used to diagnose HIV and Human T-Cell Lymphotropic Virus primarily in reference laboratories and blood banks, the company said.